Major Histocompatibility Complex class II–T cell receptor complex (MHC II–TCR)

The Major Histocompatibility Complex class II–T cell receptor (MHC II–TCR) immune interface is a specialized molecular junction between antigen-presenting cells (APCs) and CD4+ T lymphocytes (PMID: 10611914). It consists of a peptide fragment nested within the groove of an MHC class II molecule, which is then recognized by the variable regions of a T cell receptor (UniProt P01903). This interaction is the primary trigger for the activation and differentiation of T helper cells, which coordinate the broader adaptive immune response (PMID: 16337364). In healthy individuals, this system ensures the recognition of foreign pathogens while maintaining tolerance to self-proteins. However, in autoimmune conditions like rheumatoid arthritis and multiple sclerosis, the interface facilitates the inappropriate recognition of self-peptides, leading to chronic inflammation (PMID: 23391992). Pharmacological targeting of this interface aims to either block the interaction to prevent autoimmunity or enhance it to improve vaccine efficacy and cancer immunotherapy. Drugs like glatiramer acetate work by competing with myelin-derived peptides for binding to MHC II molecules, thereby shifting the immune response toward a less inflammatory state (PubChem CID 3081884). Understanding the structural biology of this interface is crucial for developing highly specific therapies that can modulate immune activity without causing broad, systemic immunosuppression.

Other names

HLA class II–TCR interfaceMHCII–TCR complexAntigen-MHC II–TCR synapseCD4+ T cell–APC interfaceMHC class II–T cell receptor immune interface

Modulation of T cell activation through competitive inhibition of peptide binding to MHC class II or interference with TCR-MHC engagement and downstream signaling.